1
|
Napoli A, Alfieri G, Scipione R, Leonardi A, Fierro D, Panebianco V, De Nunzio C, Leonardo C, Catalano C. High-intensity focused ultrasound for prostate cancer. Expert Rev Med Devices 2020; 17:427-433. [PMID: 32275187 DOI: 10.1080/17434440.2020.1755258] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
High-intensity focused ultrasound (HIFU) is a noninvasive procedure that has shown promising results in a wide range of malignant and nonmalignant conditions, including localized prostate cancer (PCa). This review aims to describe the application of HIFU in the management of patients with PCa, explaining its basic therapeutic principles, going through the main phases during aHIFU session, and providing an overview of the main available pieces of evidence from literature. HIFU treatment for prostate cancer is increasingly performed with high success and safety. MR guidance (MR-guided HIFU) has the advantage of real-time intraprocedural thermometric feedback that ensures that the whole region of interest has been covered by critical thermal damage (and that all surrounding healthy tissues have been spared). The absence of comparative long-term trials prevents HIFU from being considered as afirst choice for the treatment of patients with PCa.
Collapse
Affiliation(s)
- Alessandro Napoli
- Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I - Sapienza University of Rome; Rome (RM), Italy
| | - Giulia Alfieri
- Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I - Sapienza University of Rome; Rome (RM), Italy
| | - Roberto Scipione
- Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I - Sapienza University of Rome; Rome (RM), Italy
| | - Andrea Leonardi
- Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I - Sapienza University of Rome; Rome (RM), Italy
| | - Davide Fierro
- Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I - Sapienza University of Rome; Rome (RM), Italy
| | - Valeria Panebianco
- Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I - Sapienza University of Rome; Rome (RM), Italy
| | - Cosimo De Nunzio
- UOC Urologia, Ospedale Sant'Andrea, Sapienza, University of Rome, Italy
| | - Costantino Leonardo
- Department of Gynecology-Obstetrics and Urology, Sapienza University of Rome; Rome (RM), Italy
| | - Carlo Catalano
- Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I - Sapienza University of Rome; Rome (RM), Italy
| |
Collapse
|
3
|
Bertrand AS, Iannessi A, Natale R, Beaumont H, Patriti S, Xiong-Ying J, Baudin G, Thyss A. Focused ultrasound for the treatment of bone metastases: effectiveness and feasibility. J Ther Ultrasound 2018; 6:8. [PMID: 30519467 PMCID: PMC6267064 DOI: 10.1186/s40349-018-0117-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2018] [Accepted: 11/01/2018] [Indexed: 12/25/2022] Open
Abstract
Background To evaluate the effectiveness and feasibility of high-intensity focused ultrasound (HIFU) for the treatment of bone metastases. Methods A single-center prospective study was made involving 17 consecutive patients with symptomatic bone metastases. Patients were treated by Focused Ultrasound (FUs) performed with magnetic resonance (MR) guidance. Surgical treatment or radiotherapy treatment was not indicated for patients who underwent FUs. Lesions were located in the appendicular and axial skeleton and consisted of secondary symptomatic lesions. The clinical course of pain was evaluated using the Visual Analog Scale (VAS) before treatment, at 1 week, and at 1 month after treatment and the Oral Morphine Equivalent Daily Dose (OMEDD) was also recorded. We used Wilcoxon signed rank test to assess change in patient pain (R CRAN software V 3.1.1). Results We observed a significant decrease in the pain felt by patients between pre- procedure and 1 week post-procedure (p = 2.9.10-4), and pre-procedure and 1 month post-procedure (p = 3.10-4). The proportion of responders according to the International Bone Metastases Consensus Working Party was: Partial Response 50% (8/16) and Complete Response 37.5% (6/16). Conclusions HIFU under MR-guidance seems to be an effective and safe procedure in the treatment of symptomatic bone lesions for patients suffering from metastatic disease. A significant decrease of patient pain was observed. Trial registration NCT01091883. Registered 24 March 2010. Level of evidence: Level 3.
Collapse
Affiliation(s)
- Anne-Sophie Bertrand
- Department of Interventional Radiology, Centre de Lutte contre le Cancer Antoine Lacassagne, 33 Avenue de Valombrose, 06100 NICE, France
| | - Antoine Iannessi
- Department of Interventional Radiology, Centre de Lutte contre le Cancer Antoine Lacassagne, 33 Avenue de Valombrose, 06100 NICE, France
| | - Romain Natale
- Department of Radiotherapy, Centre de Lutte contre le Cancer Antoine Lacassagne, 33 Avenue de Valombrose, 06100 NICE, France
| | - Hubert Beaumont
- 3Department of Statistics, University of Nice Sophia Antipolis, 28 Avenue Valrose, 06000 NICE, France
| | - Sebastien Patriti
- Department of Interventional Radiology, Centre de Lutte contre le Cancer Antoine Lacassagne, 33 Avenue de Valombrose, 06100 NICE, France
| | - Jiang Xiong-Ying
- Department of Interventional Radiology, Centre de Lutte contre le Cancer Antoine Lacassagne, 33 Avenue de Valombrose, 06100 NICE, France
| | - Guillaume Baudin
- Department of Interventional Radiology, Centre de Lutte contre le Cancer Antoine Lacassagne, 33 Avenue de Valombrose, 06100 NICE, France
| | - Antoine Thyss
- Department of Oncology, Centre de Lutte anti-Cancer Antoine Lacassagne, 33 Avenue de Valombrose, 06100 NICE, France
| |
Collapse
|
4
|
Napoli A, Bazzocchi A, Scipione R, Anzidei M, Saba L, Ghanouni P, Cozzi DA, Catalano C. Noninvasive Therapy for Osteoid Osteoma: A Prospective Developmental Study with MR Imaging-guided High-Intensity Focused Ultrasound. Radiology 2017; 285:186-196. [PMID: 28590796 DOI: 10.1148/radiol.2017162680] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Purpose To demonstrate that magnetic resonance (MR) imaging-guided high-intensity focused ultrasound (HIFU) is a safe, effective, and durable treatment option for the management of osteoid osteoma in children and young adults. Materials and Methods This prospective study was institutional review board approved and is registered with clinicaltrials.gov (identification number NCT02302651). Written informed consent was obtained from patients or their parents. Patients who had both clinical and radiologic findings that were diagnostic for nonvertebral osteoid osteoma and no contraindications to MR imaging-guided HIFU were enrolled between June 2010 and June 2013. The feasibility, safety, and clinical effectiveness of MR imaging-guided HIFU were considered primary outcomes; tumor control at imaging was considered a secondary outcome. Analyses were conducted on a per-protocol basis. Results Forty-five of the 50 recruited patients underwent MR imaging-guided HIFU. All patients were discharged without treatment-related complications. The median visual analog scale (VAS) pain score (scale, 0-10) decreased from 8 before treatment to 0 at 1-week and 1- , 6- , 12- , 24- , and 36-month follow-up. Similarly, median VAS scores for the degree to which pain interfered with sleep and physical and daily activities decreased to 0 within the 1st month after treatment and remained stable at subsequent follow-up. Overall, 39 (87%) of the 45 patients achieved and maintained a VAS score of 0 during the 3-year observation period. Quality of life, as assessed by using Functional Assessment of Cancer Therapy-Bone Pain (FACT-BP) scores (scale, 0-60 points), improved, with the median FACT-BP score of 28 (points) before treatment increasing to a median score of 55 at 1-week follow-up and 60 at 6-month and subsequent follow-ups. At (final) 36-month follow-up, MR imaging depicted an absence of residual nidus vascularity in 32 (76%) of the 42 patients who were treated with MR imaging-guided HIFU only. Conclusion The durable clinical efficacy and safety of MR imaging-guided HIFU were demonstrated. These features are evidence of the potential of MR imaging-guided HIFU to be part of a routine strategy for the treatment of osteoid osteoma. © RSNA, 2017.
Collapse
Affiliation(s)
- Alessandro Napoli
- From the Department of Radiologic, Oncologic and Pathologic Sciences (A.N., R.S., M.A., C.C.) and Pediatric Surgery Unit (D.A.C.), Sapienza University of Rome, School of Medicine, V.le Regina Elena 324, 00180 Rome, Italy; Department of Radiology, Rizzoli Orthopedic Institute, University of Bologna, Bologna, Italy (A.B.); Department of Radiology, Azienda Ospedaliero Universitaria di Cagliari - Polo di Monserrato, University of Cagliari, Cagliari, Italy (L.S.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.G.)
| | - Alberto Bazzocchi
- From the Department of Radiologic, Oncologic and Pathologic Sciences (A.N., R.S., M.A., C.C.) and Pediatric Surgery Unit (D.A.C.), Sapienza University of Rome, School of Medicine, V.le Regina Elena 324, 00180 Rome, Italy; Department of Radiology, Rizzoli Orthopedic Institute, University of Bologna, Bologna, Italy (A.B.); Department of Radiology, Azienda Ospedaliero Universitaria di Cagliari - Polo di Monserrato, University of Cagliari, Cagliari, Italy (L.S.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.G.)
| | - Roberto Scipione
- From the Department of Radiologic, Oncologic and Pathologic Sciences (A.N., R.S., M.A., C.C.) and Pediatric Surgery Unit (D.A.C.), Sapienza University of Rome, School of Medicine, V.le Regina Elena 324, 00180 Rome, Italy; Department of Radiology, Rizzoli Orthopedic Institute, University of Bologna, Bologna, Italy (A.B.); Department of Radiology, Azienda Ospedaliero Universitaria di Cagliari - Polo di Monserrato, University of Cagliari, Cagliari, Italy (L.S.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.G.)
| | - Michele Anzidei
- From the Department of Radiologic, Oncologic and Pathologic Sciences (A.N., R.S., M.A., C.C.) and Pediatric Surgery Unit (D.A.C.), Sapienza University of Rome, School of Medicine, V.le Regina Elena 324, 00180 Rome, Italy; Department of Radiology, Rizzoli Orthopedic Institute, University of Bologna, Bologna, Italy (A.B.); Department of Radiology, Azienda Ospedaliero Universitaria di Cagliari - Polo di Monserrato, University of Cagliari, Cagliari, Italy (L.S.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.G.)
| | - Luca Saba
- From the Department of Radiologic, Oncologic and Pathologic Sciences (A.N., R.S., M.A., C.C.) and Pediatric Surgery Unit (D.A.C.), Sapienza University of Rome, School of Medicine, V.le Regina Elena 324, 00180 Rome, Italy; Department of Radiology, Rizzoli Orthopedic Institute, University of Bologna, Bologna, Italy (A.B.); Department of Radiology, Azienda Ospedaliero Universitaria di Cagliari - Polo di Monserrato, University of Cagliari, Cagliari, Italy (L.S.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.G.)
| | - Pejman Ghanouni
- From the Department of Radiologic, Oncologic and Pathologic Sciences (A.N., R.S., M.A., C.C.) and Pediatric Surgery Unit (D.A.C.), Sapienza University of Rome, School of Medicine, V.le Regina Elena 324, 00180 Rome, Italy; Department of Radiology, Rizzoli Orthopedic Institute, University of Bologna, Bologna, Italy (A.B.); Department of Radiology, Azienda Ospedaliero Universitaria di Cagliari - Polo di Monserrato, University of Cagliari, Cagliari, Italy (L.S.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.G.)
| | - Denis A Cozzi
- From the Department of Radiologic, Oncologic and Pathologic Sciences (A.N., R.S., M.A., C.C.) and Pediatric Surgery Unit (D.A.C.), Sapienza University of Rome, School of Medicine, V.le Regina Elena 324, 00180 Rome, Italy; Department of Radiology, Rizzoli Orthopedic Institute, University of Bologna, Bologna, Italy (A.B.); Department of Radiology, Azienda Ospedaliero Universitaria di Cagliari - Polo di Monserrato, University of Cagliari, Cagliari, Italy (L.S.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.G.)
| | - Carlo Catalano
- From the Department of Radiologic, Oncologic and Pathologic Sciences (A.N., R.S., M.A., C.C.) and Pediatric Surgery Unit (D.A.C.), Sapienza University of Rome, School of Medicine, V.le Regina Elena 324, 00180 Rome, Italy; Department of Radiology, Rizzoli Orthopedic Institute, University of Bologna, Bologna, Italy (A.B.); Department of Radiology, Azienda Ospedaliero Universitaria di Cagliari - Polo di Monserrato, University of Cagliari, Cagliari, Italy (L.S.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.G.)
| |
Collapse
|
7
|
Meissnitzer M, Meissnitzer T, Forstner R. [Gynecological tumors of the true pelvis: Radiological diagnosis for pelvic tumors made simple]. Radiologe 2016; 55:1117-30; quiz 1131. [PMID: 26610683 DOI: 10.1007/s00117-015-0045-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Tumors of the reproductive organs are among the most common female tumors. Computed tomography (CT) and magnetic resonance imaging (MRI) are used for establishing the differential diagnosis, for staging and increasingly for treatment stratification. Sonography is the first line imaging modality for assessing benign and malignant tumors of the uterus as well as ovarian and adnexal lesions. In sonographically indeterminate masses MRI is used for clarification as it allows not only a prediction of the dignity but also in most cases a specific diagnosis. The MRI examination is also superior to CT in the assessment of tumors resembling benign pelvic lesions. Whereas MRI has become established as the modality of choice for local staging and treatment planning in cancers of the uterine cervix and endometrial cancer, CT is used for staging of ovarian cancer due to the propensity for peritoneal spread outside the pelvis at the time of initial diagnosis.
Collapse
Affiliation(s)
- M Meissnitzer
- Universitätsinstitut für Radiologie, Landeskrankenhaus Salzburg, Paracelsus Medizinische Privatuniversität, Müllner Hauptstraße 48, 5020, Salzburg, Österreich
| | - T Meissnitzer
- Universitätsinstitut für Radiologie, Landeskrankenhaus Salzburg, Paracelsus Medizinische Privatuniversität, Müllner Hauptstraße 48, 5020, Salzburg, Österreich
| | - R Forstner
- Universitätsinstitut für Radiologie, Landeskrankenhaus Salzburg, Paracelsus Medizinische Privatuniversität, Müllner Hauptstraße 48, 5020, Salzburg, Österreich.
| |
Collapse
|
8
|
Hsiao YH, Kuo SJ, Tsai HD, Chou MC, Yeh GP. Clinical Application of High-intensity Focused Ultrasound in Cancer Therapy. J Cancer 2016; 7:225-31. [PMID: 26918034 PMCID: PMC4747875 DOI: 10.7150/jca.13906] [Citation(s) in RCA: 81] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Accepted: 12/03/2015] [Indexed: 12/25/2022] Open
Abstract
The treatment of cancer is an important issue in both developing and developed countries. Clinical use of ultrasound in cancer is not only for the diagnosis but also for the treatment. Focused ultrasound surgery (FUS) is a noninvasive technique. By using the combination of high-intensity focused ultrasound (HIFU) and imaging method, FUS has the potential to ablate tumor lesions precisely. The main mechanisms of HIFU ablation involve mechanical and thermal effects. Recent advances in HIFU have increased its popularity. Some promising results were achieved in managing various malignancies, including pancreas, prostate, liver, kidney, breast and bone. Other applications include brain tumor ablation and disruption of the blood-brain barrier. We aim at briefly outlining the clinical utility of FUS as a noninvasive technique for a variety of types of cancer treatment.
Collapse
Affiliation(s)
- Yi-Hsuan Hsiao
- 1. School of Medicine, Chung Shan Medical University, Taichung, Taiwan; 2. Department of Obstetrics and Gynecology, Changhua Christian Hospital, Changhua, Taiwan
| | - Shou-Jen Kuo
- 3. Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua, Taiwan
| | - Horng-Der Tsai
- 2. Department of Obstetrics and Gynecology, Changhua Christian Hospital, Changhua, Taiwan
| | - Ming-Chih Chou
- 1. School of Medicine, Chung Shan Medical University, Taichung, Taiwan
| | - Guang-Perng Yeh
- 1. School of Medicine, Chung Shan Medical University, Taichung, Taiwan; 2. Department of Obstetrics and Gynecology, Changhua Christian Hospital, Changhua, Taiwan
| |
Collapse
|
9
|
Trumm CG, Stahl R, Peller M, Clevert DA, Huber A, Reiser MF, Matzko M. [MRI for monitoring of high intensity focused ultrasound: current developments]. Radiologe 2013; 53:1001-8. [PMID: 24170287 DOI: 10.1007/s00117-012-2463-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
With respect to monitoring of high intensity focused ultrasound (HIFU), synonym focused ultrasound (FUS) treatment, magnetic resonance imaging (MRI) is characterized by several advantageous properties: the precise definition and morphological characterization of the target area (before and after the intervention), the real-time visualization of the treatment effect by thermal imaging (during the intervention) and in the sense of a stereotactic system, the 3-dimensional localization of the target lesion, planning of the target volume and assessment of the achieved ablation volume (before and during the intervention). Non-enhanced T2-weighted multislice MR images are acquired for planning of the intervention. For temperature monitoring (comprising thermometry and thermodosimetry), the temperature-dependent shift of proton resonance frequency (PRFS) is most frequently employed. This method is independent of the treated tissue type or thermally induced tissue changes and facilitates a relative measurement of the temperature change based on a reference value. Future MRI applications include diffusion-weighted MRI (DWI-MRI; for the intrainterventional estimation of treatment efficacy), dynamic contrast-enhanced MRI (DCE-MRI, for the prediction of the potential and assessment of the treatment effect achieved) and motion-corrected temperature monitoring (referenceless and multibaseline thermometry).
Collapse
Affiliation(s)
- C G Trumm
- Institut für Klinische Radiologie, Klinikum der Ludwig-Maximilians-Universität München, Campus Großhadern, Marchioninistr. 15, 81377, München, Deutschland,
| | | | | | | | | | | | | |
Collapse
|